−1.890CHF
−61.98 MCHF
7.04 MCHF
28.86 M
About MOLECULAR PARTNERS N
Sector
Industry
CEO
Patrick Amstutz
Website
Headquarters
Schlieren
Employees (FY)
182
Founded
2004
ISIN
CH0256379097
FIGI
BBG0076L94L0
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MOLN is 3.370 CHF — it has increased by 0.60% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange MOLECULAR PARTNERS N stocks are traded under the ticker MOLN.
MOLECULAR PARTNERS N is going to release the next earnings report on May 16, 2024. Keep track of upcoming events with our Earnings Calendar.
MOLN stock is 2.90% volatile and has beta coefficient of 0.44. Check out the list of the most volatile stocks — is MOLECULAR PARTNERS N there?
One year price forecast for MOLECULAR PARTNERS N has a max estimate of 15.000 CHF and a min estimate of 3.000 CHF.
MOLN earnings for the last quarter are −0.57 CHF per share, whereas the estimation was −0.72 CHF resulting in a 20.83% surprise. The estimated earnings for the next quarter are −0.55 CHF per share. See more details about MOLECULAR PARTNERS N earnings.
MOLECULAR PARTNERS N revenue for the last quarter amounts to 2.50 M CHF despite the estimated figure of 1.40 M CHF. In the next quarter revenue is expected to reach 400.00 K CHF.
Yes, you can track MOLECULAR PARTNERS N financials in yearly and quarterly reports right on TradingView.
MOLN stock has fallen by 2.32% compared to the previous week, the month change is a 3.71% fall, over the last year MOLECULAR PARTNERS N has showed a 38.05% decrease.
MOLN net income for the last quarter is −19.78 M CHF, while the quarter before that showed −11.44 M CHF of net income which accounts for −72.92% change. Track more MOLECULAR PARTNERS N financial stats to get the full picture.
Today MOLECULAR PARTNERS N has the market capitalization of 110.11 M, it has increased by 7.26% over the last week.
No, MOLN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MOLN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MOLECULAR PARTNERS N stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 182.00 employees. See our rating of the largest employees — is MOLECULAR PARTNERS N on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MOLECULAR PARTNERS N technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MOLECULAR PARTNERS N stock shows the sell signal. See more of MOLECULAR PARTNERS N technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MOLECULAR PARTNERS N future price: according to them, MOLN price has a max estimate of 15.00 CHF and a min estimate of 3.00 CHF. Read a more detailed MOLECULAR PARTNERS N forecast: see what analysts think of MOLECULAR PARTNERS N and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MOLECULAR PARTNERS N EBITDA is −58.69 M CHF, and current EBITDA margin is −833.87%. See more stats in MOLECULAR PARTNERS N financial statements.